Market capitalization | $1.41m |
Enterprise Value | $-5.82m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.37 |
P/B ratio (TTM) P/B ratio | 0.15 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-17.16m |
Free Cash Flow (TTM) Free Cash Flow | $-15.77m |
Cash position | $12.57m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a NeuBase Therapeutics Inc forecast:
3 Analysts have issued a NeuBase Therapeutics Inc forecast:
Sep '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.19 -1.19 |
6%
6%
|
|
EBITDA | -16 -16 |
50%
50%
|
EBIT (Operating Income) EBIT | -17 -17 |
48%
48%
|
Net Profit | -17 -17 |
50%
50%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington's Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.
Head office | United States |
CEO | Todd Branning |
Employees | 37 |
Founded | 2009 |
Website | www.neubasetherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.